130 related articles for article (PubMed ID: 14661035)
1. A distinct phenotype characterizes tumors from a putative genetic trait involving chondrosarcoma and breast cancer occurring in the same patient.
Cleton-Jansen AM; Timmerman MC; van de Vijver MJ; van Asperen CJ; Kroon HM; Eilers PH; Hogendoorn PC
Lab Invest; 2004 Feb; 84(2):191-202. PubMed ID: 14661035
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors.
Honrado E; Osorio A; Palacios J; Milne RL; Sánchez L; Díez O; Cazorla A; Syrjakoski K; Huntsman D; Heikkilä P; Lerma E; Kallioniemi A; Rivas C; Foulkes WD; Nevanlinna H; Benítez J
J Clin Oncol; 2005 Oct; 23(30):7503-11. PubMed ID: 16234517
[TBL] [Abstract][Full Text] [Related]
3. Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients.
Kilpivaara O; Bartkova J; Eerola H; Syrjäkoski K; Vahteristo P; Lukas J; Blomqvist C; Holli K; Heikkilä P; Sauter G; Kallioniemi OP; Bartek J; Nevanlinna H
Int J Cancer; 2005 Feb; 113(4):575-80. PubMed ID: 15472904
[TBL] [Abstract][Full Text] [Related]
4. Synchronous multifocal bone sarcomas--a case report and molecular pathologic investigation.
Walter H; Schneider-Stock R; Mellin W; Günther T; Nebelung W; Roessner A
Gen Diagn Pathol; 1995 May; 141(1):67-74. PubMed ID: 8542510
[TBL] [Abstract][Full Text] [Related]
5. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
Lancet; 1997 May; 349(9064):1505-10. PubMed ID: 9167459
[TBL] [Abstract][Full Text] [Related]
6. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
7. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
[TBL] [Abstract][Full Text] [Related]
8. The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.
Oldenburg RA; Kroeze-Jansema K; Kraan J; Morreau H; Klijn JG; Hoogerbrugge N; Ligtenberg MJ; van Asperen CJ; Vasen HF; Meijers C; Meijers-Heijboer H; de Bock TH; Cornelisse CJ; Devilee P
Cancer Res; 2003 Dec; 63(23):8153-7. PubMed ID: 14678969
[TBL] [Abstract][Full Text] [Related]
9. Molecular genetic characterization of both components of a dedifferentiated chondrosarcoma, with implications for its histogenesis.
Bovée JV; Cleton-Jansen AM; Rosenberg C; Taminiau AH; Cornelisse CJ; Hogendoorn PC
J Pathol; 1999 Dec; 189(4):454-62. PubMed ID: 10629543
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes.
Nagel JH; Peeters JK; Smid M; Sieuwerts AM; Wasielewski M; de Weerd V; Trapman-Jansen AM; van den Ouweland A; Brüggenwirth H; van I Jcken WF; Klijn JG; van der Spek PJ; Foekens JA; Martens JW; Schutte M; Meijers-Heijboer H
Breast Cancer Res Treat; 2012 Apr; 132(2):439-48. PubMed ID: 21614566
[TBL] [Abstract][Full Text] [Related]
11. Uncovering the genomic heterogeneity of multifocal breast cancer.
Desmedt C; Fumagalli D; Pietri E; Zoppoli G; Brown D; Nik-Zainal S; Gundem G; Rothé F; Majjaj S; Garuti A; Carminati E; Loi S; Van Brussel T; Boeckx B; Maetens M; Mudie L; Vincent D; Kheddoumi N; Serra L; Massa I; Ballestrero A; Amadori D; Salgado R; de Wind A; Lambrechts D; Piccart M; Larsimont D; Campbell PJ; Sotiriou C
J Pathol; 2015 Aug; 236(4):457-66. PubMed ID: 25850943
[TBL] [Abstract][Full Text] [Related]
12. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts.
Bell DW; Kim SH; Godwin AK; Schiripo TA; Harris PL; Haserlat SM; Wahrer DC; Haiman CA; Daly MB; Niendorf KB; Smith MR; Sgroi DC; Garber JE; Olopade OI; Le Marchand L; Henderson BE; Altshuler D; Haber DA; Freedman ML
Int J Cancer; 2007 Dec; 121(12):2661-7. PubMed ID: 17721994
[TBL] [Abstract][Full Text] [Related]
13. Possible association of p53 overexpression and mutation with high-grade chondrosarcoma.
Dobashi Y; Sugimura H; Sato A; Hirabayashi T; Kanda H; Kitagawa T; Kawaguchi N; Imamura T; Machinami R
Diagn Mol Pathol; 1993 Dec; 2(4):257-63. PubMed ID: 8118603
[TBL] [Abstract][Full Text] [Related]
14. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.
Vahteristo P; Bartkova J; Eerola H; Syrjäkoski K; Ojala S; Kilpivaara O; Tamminen A; Kononen J; Aittomäki K; Heikkilä P; Holli K; Blomqvist C; Bartek J; Kallioniemi OP; Nevanlinna H
Am J Hum Genet; 2002 Aug; 71(2):432-8. PubMed ID: 12094328
[TBL] [Abstract][Full Text] [Related]
15. Dedifferentiated peripheral chondrosarcoma: a clinicopathologic, immunohistochemical, and molecular analysis of four cases.
Franchi A; Baroni G; Sardi I; Giunti L; Capanna R; Campanacci D
Virchows Arch; 2012 Mar; 460(3):335-42. PubMed ID: 22350005
[TBL] [Abstract][Full Text] [Related]
16. Association between the CHEK2*1100delC germ line mutation and estrogen receptor status.
de Bock GH; Mourits MJ; Schutte M; Krol-Warmerdam EM; Seynaeve C; Blom J; Brekelmans CT; Meijers-Heijboer H; van Asperen CJ; Cornelisse CJ; Devilee P; Tollenaar RA; Klijn JG
Int J Gynecol Cancer; 2006; 16 Suppl 2():552-5. PubMed ID: 17010071
[TBL] [Abstract][Full Text] [Related]
17. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.
Chrisanthar R; Knappskog S; Løkkevik E; Anker G; Østenstad B; Lundgren S; Berge EO; Risberg T; Mjaaland I; Maehle L; Engebretsen LF; Lillehaug JR; Lønning PE
PLoS One; 2008 Aug; 3(8):e3062. PubMed ID: 18725978
[TBL] [Abstract][Full Text] [Related]
18. Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.
Aloraifi F; Alshehhi M; McDevitt T; Cody N; Meany M; O'Doherty A; Quinn CM; Green AJ; Bracken A; Geraghty JG
Eur J Surg Oncol; 2015 May; 41(5):641-6. PubMed ID: 25736863
[TBL] [Abstract][Full Text] [Related]
19. Two new CHEK2 germ-line variants detected in breast cancer/sarcoma families negative for BRCA1, BRCA2, and TP53 gene mutations.
Manoukian S; Peissel B; Frigerio S; Lecis D; Bartkova J; Roversi G; Radice P; Bartek J; Delia D
Breast Cancer Res Treat; 2011 Nov; 130(1):207-15. PubMed ID: 21562711
[TBL] [Abstract][Full Text] [Related]
20. [CHEK2-mutation in Dutch breast cancer families: expanding genetic testing for breast cancer].
Adank MA; Hes FJ; van Zelst-Stams WA; van den Tol MP; Seynaeve C; Oosterwijk JC
Ned Tijdschr Geneeskd; 2015; 159():A8910. PubMed ID: 26332814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]